Abstract
Purpose
To evaluate the clinical and visual outcome of an intravitreal injection of triamcinolone in patients with diabetic macular oedema refractory to laser treatment.
Material and methods
Prospective, interventional nonrandomised case series of 24 eyes of 24 patients that underwent intravitreal injection of 4 mg triamcinolone for chronic diabetic macular oedema refractory to previous laser treatment. All patients had best corrected visual acuity (bcva) on the LogMAR scale, near vision, slit-lamp biomicroscopy for the presence of clinically significant macular oedema, and intraocular pressure check at 1, 3, and 6 months.
Results
The average duration of macular oedema before the injection was 38.2 months (range=6–120 months) with the mean number of laser treatments before the injection being 2.2 (range=1–5). The visual acuity improved in 19 of the 23 (83%) eyes at 1 month, 16 of the 21 eyes (76%) at 3 months and six of 11 eyes (55%) at 6 months follow-up. The mean bcva improved by an average of 10, nine, and six letters, respectively, compared to the baseline at 1, 3, and 6 months (P=0.0002 at 1 month and 0.001 at 3 months with the Wilcoxon signed-ranked test). The intraocular pressure rose by an average of 2.4, 2.8, and 2.7 mmHg at the same follow-up visits.
Conclusion
Intravitreal triamcinolone appears to be promising in the short term, for improving the vision in eyes with chronic diabetic macular oedema unresponsive to conventional laser treatment. Randomised controlled trials utilising varying doses of steroid are now required to define optimum treatment regimens.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991; 98 (5 Suppl): 741–756.
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103 (12): 1796–1806.
Bailey CC, Sparrow JM, Grey RH, Cheng H . The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye 1999; 13 ( Part 2): 151–159.
Schatz H, Madeira D, McDonald HR, Johnson RN . Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular oedema. Arch Ophthalmol 1991; 109 (11): 1549–1551.
Jonas JB, Hayler JK, Panda-Jonas S . Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064–1067.
Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Bison F . Exudative macular degeneration and intravitreal triamcinolone:18 month follow up. Aust NZ J Ophthalmol 1998; 26: 277–281.
Karacorlu M, Ozdemir S, Karacorlu S . Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 2003; 81 (6): 648–652.
Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshal J . Intravitreal triamcinolone for uveitic cystoid macular oedema: an optical coherence tomography study. Ophthalmology 2001; 108: 765–772.
Young S, Larkin G, Branley M, Lightman S . Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001; 29: 2–6.
Jonas JB, Kreissig I, Söfker A, Degenring RF . Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2003; 121: 57–61.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002; 109: 920–927.
Jonas JB, Söfker A . Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425–427.
Tano Y, Chandler D, Machemer R . Treatment of intraocular proliferation with intravitreal injection of tramcinolone acetonide. Am J Ophthalmol 1980; 90: 810–816.
Machemer R, Sugita G, Tano Y . Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77: 171–180.
Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB, Miller M . Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110 (4): 681–686.
Jonas JB, Kreissig I, Degenring R . Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2002; 86: 1450–1451.
Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA . Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121 (9): 1279–1282.
Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A . Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23 (5): 686–691.
Author information
Authors and Affiliations
Additional information
Presented in part at the Midland Ophthalmological Society meeting, 2003.
Rights and permissions
About this article
Cite this article
Negi, A., Vernon, S., Lim, C. et al. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye 19, 747–751 (2005). https://doi.org/10.1038/sj.eye.6701636
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701636
Keywords
This article is cited by
-
Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells
Graefe's Archive for Clinical and Experimental Ophthalmology (2009)
-
Outcome of intravitreal triamcinolone acetonide in postoperative cystoid macular oedema
Eye (2008)
-
Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years
Eye (2007)
-
Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection
Eye (2007)
-
Intravitreal triamcinolone for the treatment of macular oedema
Eye (2006)
